Surviving the current economic turbulence has added new challenges and complexity to an industry already weakened by shortened R&D output, increased pricing pressures and shifting stakeholder expectations. As pharmaceutical leaders face critical strategic choices -- choices that have the potential to change everything about today’s “big pharma” business model -- there is an urgency to accelerate change.
Ernst & Young’s Global Pharmaceutical Center brings together our worldwide team of professionals to help you achieve your potential — a team with deep experience in providing assurance, tax, transaction and advisory services to pharmaceutical companies around the globe. As pharmaceutical companies strive for transformational strategies to both create and sustain value, we can help you move forward and lay the groundwork for an enduring enterprise.
We also publish a series of industry-leading reports and articles that provide timely points of view on business issues from around the world. So you get practical advice on the right way forward for your organization. Read more about challenges in the pharmaceuticals industry in our report Progressions.
The excitement around new science and technologies, the encouraging demographics of the global population, the improving standard of living and longer life spans enjoyed by many countries, all point to a wealth of opportunities ahead. We look forward to working with you as you execute for success.
Lessons from change: the life sciences industry
How can you manage your company through the recession and position yourself for growth? After interviewing thousands of life sciences executives, we identified some overarching themes. From managing risks to improving capital allocation, we reveal the lessons that could mean the difference between surviving and thriving in the new economic environment.
Contacts
Timur Pulatov Partner, Head of Transaction Advisory Services, Central Asia and Caucasus Office: Almaty Tel.: +7 (727) 258 5960 Fax: +7 (727) 258 5961
/$FILE/14L00243.JPG)